Visiopharm
H├╕rsholm
About Visiopharm
Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras. Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis. Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.7M
- Last round: Series Unknown (Sep 2020)
- Website: visiopharm.com
- Phone: +4588202088
Industries & Categories
Health Care, Health Diagnostics, Software
Social Profiles
Canonical: https://fsome.com/organization/visiopharm-38248 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.